TerrAscend Seeks Share Consolidation to Meet Uplisting Requirements

For most of its existence, the U.S. cannabis industry has watched the major American stock exchanges from the outside. Federal law treated marijuana as a Schedule I controlled substance, and exchanges would not list companies that touched the plant in the United States. On June 29, 2026, TerrAscend Corp. signaled that it believes that wall is starting to come down, and it began preparing to meet the uplisting requirements on the other side.

In a press release filed with a Form 8-K, the company announced a special shareholder meeting to approve a share consolidation, a reverse split, aimed squarely at the minimum share price standards of major U.S. exchanges.

The regulatory opening

TerrAscend pointed to a specific change. On April 23, 2026, according to the release, the U.S. Department of Justice issued a final rule moving marijuana in FDA-approved drug products, and marijuana subject to a state medical marijuana license, from Schedule I to Schedule III. The company was careful to note the limits: non-medical cannabis remains a Schedule I substance, with significant legal restrictions still in place.

Executive Chairman Jason Wild framed the change in confident terms, saying uplisting is “no longer a question of if,” but of when. The release did not name a target exchange or a date.

Rescheduling opened a door for cannabis operators; a reverse split is how a company makes sure it can fit through it.

How the consolidation works

The proposal asks shareholders to approve a consolidation of common shares, exchangeable shares and preferred shares at a ratio the board would choose within a range of one post-consolidation share for every five to twenty existing shares. The board would decide both the exact ratio and the timing, and could implement the consolidation at any point within 12 months after approval.

The record date for the meeting was set for June 30, 2026. The special meeting was scheduled for August 24, 2026, with a proxy voting deadline of 1:00 p.m. Eastern Time on August 20.

Why price matters for uplisting requirements

U.S. exchanges set minimum bid or closing price thresholds for initial listing, alongside requirements for equity, market value, publicly held shares and holders. A company whose shares trade at a low price can satisfy the price test by consolidating, since each new share represents several old ones. The total value of a holder’s position does not change at the moment of consolidation, but the per-share price rises proportionally.

Reverse splits carry trade-offs. They reduce the number of shares outstanding, which can thin trading, and market reaction afterward is not guaranteed. Choosing a ratio range rather than a fixed number gives the board room to set the post-split price at a level that clears the threshold with a margin.

Who is affected

TerrAscend currently trades on the Toronto Stock Exchange under TSND and on the OTCQX under TSNDF. It operates cultivation, processing, manufacturing and retail businesses in Pennsylvania, New Jersey, Maryland, Ohio and California, along with retail in Canada, and its brands include The Apothecarium, Cookies, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana and Valhalla Confections. The company already files with the SEC and reports under U.S. GAAP, which shortens the path to an exchange.

U.S. investors who are barred from OTC holdings, other multistate cannabis operators and the exchanges themselves are all watching how far the rescheduling rule goes in practice.

What to watch

Key milestones include the August 24 vote, the ratio the board chooses, any exchange listing application, and whether exchanges conclude that companies with adult-use operations can list while non-medical cannabis remains in Schedule I.